Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the EU / 2025-522058-38-00
Authorised, not yet recruiting Phase II

MOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.

2025-522058-38-00 · tracked via the Priya Life Science EU tracker
Sponsor
Centre Leon Berard
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Pathological Conditions, Signs and Symptoms
Decision date
09/10/2026
Enrollment target
200
Sites
France

Condition studied

HER2-positive rare cancer, HER2 positive non-small cell lung cancer, HER-positive non rare tumor type, HER2 positive bladder cancer

Investigational medicinal product(s)

Enhertu 100 mg powder for concentrate for solution for infusion

Every trial of Trastuzumab deruxtecan across our registers →

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Objective response rate (ORR-18W) as per RECIST V1.1. as per investigator assessment, per cohort

Endpoint detail

Duration of response (DoR) Progression free rate at 18W (PFR-18W) Progression-Free survival (PFS) Overall survival (OS) Safety as per NCI-CTCAE V6.0, EQ-5D-5L questionnaire, Length of hospital stays (LOS) including acute care hospitalizations (resuscitation unit, intensive care, etc.), home care hospitalizations and follow-up and rehabilitation care

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522058-38-00 on CTIS ↗ ← All trials in the EU